CAGNONI PABLO J sold $1.4M of INCY

Incyte has reached an agreement with the Centers for Medicare & Medicaid Services (CMS) to enhance access to its medicines. The deal aims to improve patient access to Incyte's treatments, according to the company.

Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.

Incyte (INCY) and Revolution Medicines (RVMD) are competing in the KRAS inhibitor market. RBC noted INCY's upcoming ESMO data for its KRAS G12D inhibitor, while Bernstein raised RVMD's price target. RVMD received FDA approval for Rasonque. INCY reported Q2 2026 revenue of $1.67B, while RVMD had no product revenue but $3.9B in cash. Institutional investors favor RVMD, with notable holdings by Farallon Capital and Baker Bros. Advisors.

Incyte (INCY) reported Q2 2026 earnings and revenue above expectations, driven by strong demand for Jakafi and Opzelura. The company raised its 2026 net product revenue guidance and received FDA approval for Niktimvo, adding a new therapy to its portfolio. Analysts project varying revenue and earnings estimates for 2029, with the company targeting $5.8 billion in revenue and $1.1 billion in earnings, while the lowest estimates predict $5.4 billion in revenue and $1.2 billion in earnings.

Incyte (INCY) raised its 2026 revenue forecast to $5.13B-$5.26B after a CMS settlement. Q2 2026 net sales rose 40% to $1.49B, and adjusted EPS was $3.09, beating estimates. Analysts expect FY 2026 EPS to decrease 52.7% YoY to $2.64. The stock has a 'Moderate Buy' consensus rating, with a mean price target of $127.09.

Halozyme Therapeutics (HALO) and Incyte (INCY) announced a global collaboration using Incyte’s INCA033989 subcutaneous formulation with Halozyme’s ENHANZE delivery. Halozyme will receive upfront, milestones and royalties, while Incyte can add two targets. The article also compares Q2 2026 results and guidance for both companies.